| Clinical radioimmunotherapy—the role of radiobiology JP Pouget, I Navarro-Teulon, M Bardiès, N Chouin, G Cartron, A Pèlegrin, ... Nature reviews Clinical oncology 8 (12), 720-734, 2011 | 270 | 2011 |
| Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons JP Pouget, L Santoro, L Raymond, N Chouin, M Bardiès, ... Radiation research 170 (2), 192-200, 2008 | 130 | 2008 |
| EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands K Sjögreen Gleisner, N Chouin, PM Gabina, F Cicone, S Gnesin, ... European journal of nuclear medicine and molecular imaging 49 (6), 1778-1809, 2022 | 89 | 2022 |
| Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb V Boudousq, L Bobyk, M Busson, V Garambois, M Jarlier, ... PLoS One 8 (7), e69613, 2013 | 67 | 2013 |
| The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy C Chiesa, K Sjogreen Gleisner, G Flux, J Gear, S Walrand, K Bacher, ... European Journal of Nuclear Medicine and Molecular Imaging 44, 1783-1786, 2017 | 63 | 2017 |
| Tumor immunotargeting using innovative radionuclides F Kraeber-Bodéré, C Rousseau, C Bodet-Milin, C Mathieu, F Guérard, ... International journal of molecular sciences 16 (2), 3932-3954, 2015 | 61 | 2015 |
| Comparison of electron dose-point kernels in water generated by the Monte Carlo codes, PENELOPE, GEANT4, MCNPX, and ETRAN H Uusijärvi, N Chouin, P Bernhardt, L Ferrer, M Bardies, ... Cancer biotherapy and radiopharmaceuticals 24 (4), 461-467, 2009 | 56 | 2009 |
| From fixed activities to personalized treatments in radionuclide therapy: lost in translation? GD Flux, K Sjogreen Gleisner, C Chiesa, M Lassmann, N Chouin, J Gear, ... European Journal of Nuclear Medicine and Molecular Imaging 45, 152-154, 2018 | 52 | 2018 |
| Promising Scandium Radionuclides for Nuclear Medicine: A Review on the Production and Chemistry up to In Vivo Proofs of Concept S Huclier-Markai, C Alliot, R Kerdjoudj, M Mougin-Degraef, N Chouin, ... Cancer biotherapy & radiopharmaceuticals 33 (8), 316-329, 2018 | 50 | 2018 |
| Implementing dosimetry in GATE: Dose-point kernel validation with GEANT4 4.8. 1 L Ferrer, N Chouin, A Bitar, A Lisbona, M Bardiès Cancer biotherapy & radiopharmaceuticals 22 (1), 125-129, 2007 | 50 | 2007 |
| Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model N Chouin, K Bernardeau, F Davodeau, M Cherel, A Faivre-Chauvet, ... Radiation research 171 (6), 657-663, 2009 | 38 | 2009 |
| Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma C Bailly, S Gouard, M Lacombe, P Remaud-Le Saëc, B Chalopin, ... Oncotarget 9 (10), 9061, 2018 | 37 | 2018 |
| Apoptosis and p53 are not involved in the anti-tumor efficacy of 125I-labeled monoclonal antibodies targeting the cell membrane S Paillas, V Boudousq, B Piron, N Kersual, M Bardiès, N Chouin, ... Nuclear medicine and Biology 40 (4), 471-480, 2013 | 34 | 2013 |
| Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique N Chouin, S Lindegren, SHL Frost, H Jensen, P Albertsson, R Hultborn, ... Journal of Nuclear Medicine 54 (8), 1347-1353, 2013 | 33 | 2013 |
| What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical … C Bailly, S Gouard, F Guérard, B Chalopin, T Carlier, A Faivre-Chauvet, ... International Journal of Molecular Sciences 20 (10), 2564, 2019 | 30 | 2019 |
| Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. II. Application of the microdosimetric model to experimental results N Chouin, K Bernardeau, M Bardies, A Faivre-Chauvet, M Bourgeois, ... Radiation research 171 (6), 664-673, 2009 | 29 | 2009 |
| DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapy B Piron, S Paillas, V Boudousq, A Pèlegrin, C Bascoul-Mollevi, N Chouin, ... Nuclear medicine and biology 41, e75-e83, 2014 | 25 | 2014 |
| Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model SHL Frost, T Bäck, N Chouin, R Hultborn, L Jacobsson, J Elgqvist, ... Cancer Biotherapy and Radiopharmaceuticals 28 (2), 108-114, 2013 | 25 | 2013 |
| Cure of human ovarian carcinoma solid xenografts by fractionated α-radioimmunotherapy with 211At-MX35-F (ab′) 2: Influence of absorbed tumor dose and effect on long-term survival T Bäck, N Chouin, S Lindegren, H Kahu, H Jensen, P Albertsson, S Palm Journal of Nuclear Medicine 58 (4), 598-604, 2017 | 24 | 2017 |
| Radiolabeled antibodies against müllerian-inhibiting substance receptor, type II: new tools for a theranostic approach in ovarian cancer E Deshayes, R Ladjohounlou, P Le Fur, A Pichard, C Lozza, V Boudousq, ... Journal of Nuclear Medicine 59 (8), 1234-1242, 2018 | 20 | 2018 |
Albert LisbonaInstitut de cancérologie de l'Ouest René GauducheauVerified email at ico.unicancer.fr
